Test Price
2,800 AED✅ Home Collection Available
ATXN3 Gene Spinocerebellar Ataxia Type 3 (SCA3) Genetic Test | UAE | 2800 AED | 2026 DHA Guidelines
تحليل جين ATXN3 للرنح النخاعي المخيخي من النوع الثالث (SCA3) في الإمارات | 2800 درهم | معتمد من هيئة الصحة بدبي
Executive Summary
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Certified NGS processing (Cert: INT/EGQ/2509DA/3139).
- Premium Logistics: Paid Hospital‑Grade Home Collection via ISO‑Certified Cold‑Chain transportation and VIP Mobile Phlebotomy (8 AM‑11 PM).
- Clinical Guidance: Telephonic post‑test clinical guidance to support result interpretation by a board‑certified neurologist.
- Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
الملخص التنفيذي: ضمان دقة تشخيصية بنسبة %99.9 عبر تقنية التسلسل الجيني من الجيل التالي (NGS) والمعتمدة من ISO 9001:2015. خدمة سحب منزلي فائقة الجودة بنظام سلسلة التبريد المعتمدة، مع دعم تفسير النتائج عبر استشارة هاتفية مع طبيب أعصاب معتمد. التحقق من التغطية التأمينية عبر الواتساب.
Overview
This Next-Generation Sequencing (NGS) test analyzes the ATXN3 gene to detect the CAG trinucleotide repeat expansion responsible for autosomal dominant Spinocerebellar Ataxia Type 3 (SCA3 / Machado‑Joseph disease). Results are delivered within 3‑4 weeks with pre‑ and post‑test genetic counseling support. يحدد هذا التحليل توسع تكرارات CAG في جين ATXN3 المسبب للرنح النخاعي المخيخي الوراثي السائد من النوع الثالث (داء ماشادو‑جوزيف).
| Feature | Our Test (NGS‑ATXN3) | Closest Alternative (Fragment Analysis) |
|---|---|---|
| Precision | Full‑gene coverage with exact repeat sizing and flanking variant detection | Repeat sizing only; may miss rare pathogenic variants |
| Methodology | NGS (Next‑Generation Sequencing) + orthogonal confirmation | PCR‑based fragment length analysis |
| Turnaround | 3‑4 weeks | 6‑8 weeks |
Pre‑Test Preparation
- A clinical history documenting neurological symptoms and family history of ataxia is mandatory.
- A genetic counseling session to construct a detailed pedigree chart of affected family members is strongly recommended and can be arranged prior to sample collection.
- No dietary restrictions or fasting required. Do not adjust or stop prescribed medications without physician approval.
- For patients on anticoagulants or those with severe anemia, home collection may require additional precautions – please inform us during booking.
Physician Insight & Safety Protocol
“As a neurologist, I understand the anxiety a family feels when a neurodegenerative diagnosis like SCA3 is suspected. This test provides critical molecular confirmation, but the result must always be correlated with clinical examination and family history. I encourage all patients to engage in thorough pre‑test counseling to fully comprehend the autosomal dominant inheritance pattern and its implications for at‑risk relatives.”
— Dr. Prabhakar Reddy, DHA License 61713011
⚠️ Medication & Safety Warning
Do not discontinue any prescribed medication (especially anti‑seizure, muscle relaxants, or antidepressants) without explicit consultation with your treating physician.
Exclusion Criteria & Emergency Red Flags
- Exclusion: Individuals with an active severe infection, uncontrolled coagulopathy, or inability to provide informed consent without a legal guardian (UAE CDS Law 2026 requirements for minors).
- Red Flags (seek urgent care): Sudden deterioration in balance, speech, or swallowing; new‑onset seizures; or any signs of increased intracranial pressure (e.g., severe headache with vomiting). These symptoms may indicate an unrelated acute neurological event and should be evaluated immediately, irrespective of the scheduled test.
Patient FAQ & Clinical Guidance
What exactly does the ATXN3 NGS test detect?
This test identifies the abnormal CAG trinucleotide repeat expansion in the ATXN3 gene that definitively confirms a molecular diagnosis of Spinocerebellar Ataxia Type 3 (SCA3), also known as Machado‑Joseph disease. يكتشف هذا التحليل توسع تكرارات CAG الشاذة في جين ATXN3، مما يؤكد التشخيص الجزيئي للرنح النخاعي المخيخي من النوع الثالث (داء ماشادو‑جوزيف).
How long does the result take and what happens after?
Results are reported within 3 to 4 weeks from sample receipt; once available, a telephonic clinical guidance session with a DHA‑licensed neurologist is scheduled to explain the findings in the context of your family history and clinical picture. تُصدر النتائج خلال 3 إلى 4 أسابيع من استلام العينة، ومن ثم تُحدد جلسة توجيه سريري هاتفية مع طبيب أعصاب مرخص من هيئة الصحة بدبي لشرح النتائج.
Is this covered by insurance in the UAE?
We provide direct billing verification; send your insurance card and Emirates ID via WhatsApp to +971 54 548 8731, and our team will confirm coverage under your neurological diagnostic benefits within 1 working day. نوفر خدمة التحقق المباشر من التغطية التأمينية؛ أرسل صورة بطاقة التأمين والهوية الإماراتية عبر الواتساب إلى +971 54 548 8731 وسيتم الرد خلال يوم عمل واحد.
ISO 9001:2015 Certified Facility (Cert: INT/EGQ/2509DA/3139) · DHA/MOHAP Licensed (Facility No. 9834453)
Compliant with UAE Federal Decree‑Law No. 41 of 2024 (Article 87), CDS Law 2026 (Minors), and UAE Personal Data Protection Law (PDPL). All genetic data is handled under strict confidentiality and used solely for diagnostic purposes.
Methodology: Next‑Generation Sequencing (NGS) with orthogonal confirmation, aligned to 2026 AI‑validated clinical datasets.
24/7 Patient Support & Home Collection: +971 54 548 8731 (WhatsApp & Voice)
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians